- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | Prenetics divests 3PL distribution business in all-stock deal valued at up to $13M | 2 | Seeking Alpha | ||
| 05.01. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.12.25 | David Beckham's Prenetics halts $1B Bitcoin plan to focus on IM8 health brand | 1 | iNVEZZ.com | ||
| 30.12.25 | Prenetics halts Bitcoin purchases to focus on consumer health brand, IM8 | 2 | Seeking Alpha | ||
| 30.12.25 | Prenetics Global Limited: Prenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8 | 186 | GlobeNewswire (Europe) | Company's Capital and Strategic Focus Now Exclusively Focused on IM8 IM8 FY 2026 Revenue Projected to Reach $180 - $200 Million CHARLOTTE, N.C., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global... ► Artikel lesen | |
| 23.12.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Prenetics Global Limited: Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure | 292 | GlobeNewswire (Europe) | CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and... ► Artikel lesen | |
| 11.12.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.11.25 | Prenetics executives purchase $1.4 million in company stock | 1 | Investing.com | ||
| 24.11.25 | Prenetics executives buy $1.45M in company stock | 2 | Seeking Alpha | ||
| 24.11.25 | Prenetics-Management investiert 1,45 Millionen US-Dollar in eigene Aktien | 1 | Investing.com Deutsch | ||
| 24.11.25 | Prenetics Global Limited: Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million | 2 | GlobeNewswire (USA) | ||
| 17.11.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.11.25 | Prenetics Global Limited: Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth | 414 | GlobeNewswire (Europe) | IM8's Strong Unit Economics-60% Margins and 3.9-Month Payback-Central to Cantor's Bullish Outlook Cantor Notes PRE's ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company's Financial... ► Artikel lesen | |
| 12.11.25 | Cantor Fitzgerald lowers Prenetics stock price target to $31 on Q3 results | 2 | Investing.com | ||
| 10.11.25 | Prenetics Global GAAP EPS of -$0.53, revenue of $23.6M | 3 | Seeking Alpha | ||
| 10.11.25 | Prenetics Global Limited: Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR by December 2025, Fastest Supplement Brand Growth in Industry History | 222 | GlobeNewswire (Europe) | Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M... ► Artikel lesen | |
| 10.11.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.11.25 | Prenetics Global's Earnings: A Preview | 1 | Benzinga.com | ||
| 04.11.25 | Prenetics' IM8 achieves record $9M in revenue for October | 3 | Seeking Alpha |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANSINO BIOLOGICS | 4,032 | -4,95 % | CANSINOBIO Expects 2025 to Swing to Profit of at Least RMB24.5M | ||
| SINO BIOPHARM | 0,721 | +4,10 % | SINO BIOPHARM's TQA3605 'Core Protein Allosteric Modulator' for Chronic Hepatitis B Achieves Primary Endpoint in Phase II Clinical Trials | ||
| GENSCRIPT BIOTECH | 1,393 | 0,00 % | GENSCRIPT BIO (01548): VOLUNTARY ANNOUNCEMENT: APPOINTMENT OF DIRECTOR BY LEGEND BIOTECH CORPORATION | ||
| QUANTUM-SI | 1,215 | +0,41 % | Quantum-Si Inc - 8-K, Current Report | ||
| INNOVENT BIOLOGICS | 8,650 | -1,14 % | Innovent Biologics: Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma | SAN FRANCISCO and SUZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that... ► Artikel lesen | |
| SCILEX | 9,320 | -3,72 % | Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, ... | PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault AI Inc. ("Datavault AI" or the "Company") (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization... ► Artikel lesen | |
| ORIGIN AGRITECH | 1,100 | +3,77 % | Origin Agritech Limited: Origin Agritech Obtains New Licenses for Crop Seed Production and GMO Business Operations | Strategic Restructuring Positions Company to Strengthen Market Presence with Expanded Operational Capabilities
BEIJING, Oct. 24, 2025 /PRNewswire/ -- Origin Agritech... ► Artikel lesen | |
| AKESO | 12,300 | +1,65 % | AKESO (09926): CONTINUING CONNECTED TRANSACTION FURTHER INFORMATION IN RELATION TO THE CONTRACT MANUFACTURING ARRANGEMENT | ||
| QIAGEN | 45,395 | -2,23 % | Qiagen: Neue Spekulationen | Bei Qiagen gibt es erneut Übernahmegerüchte. Angeblich werden strategische Optionen, darunter auch ein Verkauf, geprüft. Demnach sondiert der Aufsichtsrat das Interesse von möglichen Käufern. Es soll... ► Artikel lesen | |
| BIONTECH | 100,30 | +1,11 % | BioNTech: FDA gewährt Fast-Track-Status für BNT113 | Die BioNTech SE hat von der U.S. Food and Drug Administration (FDA) den Fast-Track-Status für den mRNA-Krebsimmuntherapie-Kandidaten BNT113 erhalten. Die Zulassungserleichterung bezieht sich auf die... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,390 | +4,04 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| BIOMX | 7,500 | +77,73 % | Morning Market Movers: Nuwellis, BiomX, Brand Engagement Network, Blaize Holdings See Big Swings | WOONSOCKET (dpa-AFX) - At 7:02 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 306,24 | +4,15 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| ERASCA | 9,840 | +2,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,615 | +0,54 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
PRENETICS GLOBAL LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,11 % bei einem Aktienkurs von 18,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.